8-K: ImmunityBio Announces FDA Submissions and Strong Q1 Revenue Growth

ImmunityBio reports FDA submissions for ANKTIVA in bladder cancer and lymphopenia, alongside a 129% increase in Q1 revenue.

Summary

• ImmunityBio has submitted a supplemental Biologics License Application (sBLA) to the FDA for ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for papillary disease.
• The company also submitted an Expanded Access Protocol (EAP) for ANKTIVA for the treatment of lymphopenia, following a Regenerative Medicine Advanced Therapy (RMAT) designation.
• In Q1 2025, ANKTIVA unit sales volume grew 150% over Q4 2024, driven by a permanent J-code (J9028) awarded in January 2025.
• ImmunityBio achieved estimated net product revenue of approximately $16.5 million for the three-month period ended March 31, 2025, a 129% increase from $7.2 million in the prior quarter.
• ANKTIVA sales momentum continued to trend upward in 2025, with sales volume in March representing a 69% increase month-over-month from February.

Sentiment

Score: 8

Explanation: The announcement is positive due to strong revenue growth, FDA submissions, and promising clinical data. However, the preliminary nature of the financial results and regulatory uncertainties temper the overall sentiment.

Positives

• FDA submissions for ANKTIVA in new indications (papillary disease and lymphopenia) expand its potential market.
• The permanent J-code for ANKTIVA has driven significant sales growth.
• The 129% quarter-over-quarter revenue increase demonstrates strong commercial momentum.
• Clinical data shows durable complete remissions in patients with BCG-unresponsive NMIBC papillary disease treated with ANKTIVA plus BCG.
• Patients receiving ANKTIVA plus BCG achieved a 93% avoidance of cystectomy in a pivotal study.

Risks

• The reported financial results are preliminary estimates and may differ materially from the actual results in the 10-Q filing.
• FDA review and approval of the sBLA and EAP are subject to uncertainty and potential delays.
• Commercial launch execution and market access initiatives carry inherent risks.
• The company's ability to fund ongoing and anticipated clinical trials is a risk factor.
• Potential product shortages or manufacturing disruptions could impact product availability.

Future Outlook

The company anticipates continued sales momentum for ANKTIVA and is focused on securing regulatory approvals for expanded indications. They are also developing next-generation therapies and vaccines to bolster the immune system.

Industry Context

The announcement highlights ImmunityBio's efforts to expand the use of ANKTIVA in bladder cancer and address unmet needs in lymphopenia treatment. The company is positioning itself as a leader in immunotherapy with a focus on activating the natural immune system.

Comparison to Industry Standards

• The 129% quarter-over-quarter revenue growth is significant compared to other biotechnology companies in the immunotherapy space.
• The 93% cystectomy avoidance rate in the pivotal study is a notable achievement compared to standard treatments for BCG-unresponsive NMIBC.
• Companies like Merck (Keytruda) and Bristol Myers Squibb (Opdivo) are major players in the immunotherapy market, but ImmunityBio is focusing on a different mechanism of action with ANKTIVA.

Stakeholder Impact

• Shareholders: Positive impact due to revenue growth and potential for expanded market opportunities.
• Patients: Potential for new treatment options for bladder cancer and lymphopenia.
• Employees: Positive impact due to company growth and development of innovative therapies.

Next Steps

• FDA review of the sBLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC for papillary disease.
• FDA review of the EAP for ANKTIVA for the treatment of lymphopenia.
• Release of final Q1 2025 financial results in the Form 10-Q filing.
• Continued commercialization efforts for ANKTIVA.
• Further development of next-generation therapies and vaccines.

Key Dates

Keywords

ANKTIVA, ImmunityBio, NMIBC, Lymphopenia, FDA, sBLA, EAP, Revenue, BCG, Immunotherapy